nach oben

CNS Drugs

Erschienen in:

01.07.2006 | Therapy In Practice

Pharmacological Aspects of the Treatment of Conduct Disorder in Children and Adolescents

verfasst von: Dr Oleg V. Tcheremissine, Lori M. Lieving

Erschienen in: CNS Drugs | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

In recent years, the rates of psychosocial disorders in children and adolescents have increased, with behavioural manifestations of conduct disorder being one of the most common reasons for referrals to community psychiatrists. Childhood conduct problems are associated with a variety of psychiatric disorders in adult life that extend beyond antisocial behaviour. An increased awareness of the costs of conduct disorder to individuals, families and society has led to advancements in the pharmacological and nonpharmacological therapeutic modalities for this disorder. Despite this, patients with conduct disorder are difficult to treat as the patterns of maladaptive behaviours they exhibit are diverse and can vary as a function of age and sex. A multidisciplinary approach to the treatment of conduct disorder, which includes behavioural parent training, interpersonal skills training, family therapy and the use of psychotropic agents targeted at a particular cluster of symptoms, can increase the overall effectiveness of each of the applied interventions. Aggression, hyperactivity, impulsivity and mood symptoms are the most sensitive proximal targets.

Evidence suggests that antipsychotics, antidepressants, mood stabilisers, antiepileptic drugs, stimulants and adrenergic drugs can be well tolerated and effective therapeutic options for individuals with conduct disorder and comorbid psychiatric conditions. However, the most successful therapeutic outcomes are likely to be achieved by combining the current advances in psychopharmacology with behavioural and psychosocial interventions, aimed at modifying the excessive patterns of maladaptive behaviours observed in conduct disorder.

Blumstein A. Youth violence, guns, and the illicit-drug industry. J Crim Law Criminol 1995; 86(1): 10–36CrossRef

Rosenberg ML, O’Carroll PW, Powell KE. Let’s be clear: violence is a public health problem. JAMA 1992; 267(22): 3071–2PubMedCrossRef

Centers for Disease Control and Prevention. Years of potential life lost before 65: United States, 1980–1991. Morb Mortal Wkly Rep 1993; 42(130): 251–3

Kazdin A. Treatment for aggressive and antisocial children. Child Adolesc Psychiatr Clin N Am 2000; 9: 841–58PubMed

Clark DB, Jacob RG, Mezzich A. Anxiety and conduct disorder in early onset alcoholism. Ann N Y Acad Sci 1994; 708: 181–6PubMedCrossRef

Moss HB, Lynch KG. Comorbid disruptive behavior disorder symptoms and their relationship to adolescent alcohol use disorders. Drug Alcohol Depend 2001; 64: 75–83PubMedCrossRef

Myers MG, Brown SA, Mott MA. Preadolescent conduct disorder behaviors predict relapse and progression of addiction for adolescent alcohol and drug abusers. Alcohol Clin Exp Res 1995; 19: 1528–36PubMedCrossRef

Foster EM, Jones DE. The high costs of aggression: public expenditures resulting from conduct disorder. Am J Public Health 2005; 95(10): 1767–72PubMedCrossRef

Findling RL. Paediatric psychopharmacology: closing the gap between science and practice. Expert Opin Pharmacother 2001; 2(4): 523–5PubMedCrossRef

10.

American Psychiatric Association. 4th ed., text rev. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 2000

11.

Robins LN, McEvoy LT. Conduct problems as predictors of substance abuse. In: Robins LN, Rutter M, editors. Straight and deviant pathways from childhood to adulthood. New York: Cambridge University Press, 1990: 182–204

12.

Loeber R, Hay D. Key in the development of aggression and violence from childhood to early adulthood. Annu Rev Psychol 1997; 48: 371–410PubMedCrossRef

13.

Angold A, Costello EJ, Erkani A. Comorbidity. J Child Psychol Psychiatry 1999; 40(1): 57–87PubMedCrossRef

14.

World Health Organisation. ICD-10: classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization, 1992

15.

Nock MK, Kazdin AE, Hiripi E, et al. Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey Replication. Psychiatry Med 2006 Jan 26 [Epub ahead of print]

16.

Robins LN. Deviant children grown up. Baltimore (MD): Williams and Wilkins, 1966

17.

Wade TJ. Delinquency and health among adolescents: multiple outcomes of a similar social and structural process. Int J Law Psychiatry 2001; 24: 447–67PubMedCrossRef

18.

Yoshikawa H. Long-term effects of early childhood programs on social outcomes and delinquency. Future Child 1995; 5: 51-75PubMedCrossRef

19.

Pevalin DJ, Wade TJ, Brannigan A. Precursors, consequences and implications for stability and change in pre-adolescent antisocial behavior. Prev Sci 2003; 4: 123–36PubMedCrossRef

20.

Regier DA, Myers JK, Kramer M, et al. The NIMH epidemiologic catchment area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934–41PubMedCrossRef

21.

Zoccolilo M, Rogers K. Characteristics and outcome of hospitalized adolescent girls with conduct disorder. J Am Acad Child Adolesc Psychiatry 1991; 30: 973–81CrossRef

22.

Eagly AH, Steffen VJ. Gender and aggressive behavior: a meta-analytic review of the social psychological literature. Psychol Bull 1986; 100: 309–30PubMedCrossRef

23.

Maccoby EE, Jacklin CN. Sex differences in aggression: a rejoinder and reprise. Child Dev 1980; 51: 964–80PubMedCrossRef

24.

Crick NR, Grotpeter JK. Relational aggression, gender, and social-psychological adjustment. Child Dev 1995; 66: 710–22PubMedCrossRef

25.

Lagerspetz KMJ, Bjorkqvist K, Peltonen T. Is indirect aggression typical of females? Gender differences in aggressiveness in 11–12 year old children. Aggress Behav 1988; 14: 402–14

26.

Hettema JM, Prescott CA, Kendler K. The effects of anxiety, substance use and conduct disorders on risk of major depressive disorder. Psychol Med 2003; 33: 1423–32PubMedCrossRef

27.

Preskorn S, Baker B. The overlap of DSM-IV syndromes: potential implications for the practice of polypsychopharmacology, psychiatric drug development, and human genome project. J Psychiatr Pract 2002; 8: 170–7PubMedCrossRef

28.

VanPraag H. Over the mainstream: diagnostic requirements for biological psychiatric research. Psychiatry Res 1997; 72: 201–12PubMedCrossRef

29.

Paris J. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr Psychiatry 1997; 38(4): 237–42PubMedCrossRef

30.

Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193–204PubMedCrossRef

31.

Zoccolillo M, Pickles A, Quintan D, et al. The outcome of childhood conduct disorder: implications for defining adult personality disorder and conduct disorder. Psychol Med 1992; 22: 971–86PubMedCrossRef

32.

Robins LN. Sturdy childhood predictors of adult antisocial behavior: replication from longitudinal analyses. Psychol Med 1978; 8: 611–22PubMedCrossRef

33.

Quay HC, Peterson DR. Revised behavior problem checklist: professional manual. Odessa (FL): Psychological Assessment Resources,Inc., 1993

34.

Achenbach TM. Manual for child behaviour checklist and 1991 profile. Burlington (VT): University of Vermont, Department of Psychiatry, 1991

35.

Tackett JL, Krueger RF, Sawyer MG, et al. Subfactors of DSM-IV conduct disorder: evidence and connections with syndromes from the child behavior checklist. J Abnorm Child Psychol 2003; 31(6): 647–54PubMedCrossRef

36.

Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 1992; 15(1): 69–85PubMed

37.

Waddel C, Lipman E, Offord D. Conduct disorder: practice parameters for assessment, treatment, and prevention. Can J Psychiatry 1999; 44Suppl. 2: 355–405

38.

Cadoret RJ, Yates WR, Troughton E, et al. Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry 1995; 52: 42–52PubMedCrossRef

39.

Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21–9PubMedCrossRef

40.

Hundleby JD, Carpenter RA, Ross RA, et al. Adolescent drug use and other behaviors. J Child Psychol Psychiatry 1982; 23: 61–8PubMedCrossRef

41.

Donovan JE, Jessor R. Structure of problem behavior in adolescence and young adulthood. J Consult Clin Psychol 1985; 53: 890–904PubMedCrossRef

42.

Kingery PM, Pruitt BE, Hurley RS. Violence and illegal drug use among adolescents: evidence from the US National Adolescent Student Health Survey. Int J Addict 1992; 27: 1445–64PubMed

43.

Centers for Disease Control and Prevention. Youth risk behavior surveillance: United States, 2001. Morb Mortal Wkly Rep 2002: 51: SS–4

44.

Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–46PubMedCrossRef

45.

Reyes M, Buitelaar J, Toren R, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402–10PubMedCrossRef

46.

Findling RL, Blumer JL, Kauffman R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder [poster]. 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

47.

Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445–53PubMedCrossRef

48.

Malone RP, Delaney JF, Carter J, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57: 649–54PubMedCrossRef

49.

Steiner H, Peterson ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 2003; 64(10): 1183–91PubMedCrossRef

50.

Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 480–90PubMedCrossRef

51.

Armenteros JL, Lewis JE. Citalopram treatment for impulsive aggression in children and adolescents: an open pilot study.J Am Acad Child Adolesc Psychiatry 2002; 41: 522–9PubMedCrossRef

52.

Mozes T, Meiri G, Ben-Amity G, et al. Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 2005 Apr; 15(2): 259–69PubMedCrossRef

53.

Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention hyperactivity deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54(12): 1073–80PubMedCrossRef

54.

Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 1999; 38: 578–86PubMedCrossRef

55.

Hazel PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42(8): 886–94CrossRef

56.

Kaplan SL, Simms RM, Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 1994; 33: 35–44PubMedCrossRef

57.

Pappadopulus E, MacintyreII JC, Crimson ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): part II. J Am Acad Child Adolesc Psychiatry 2003; 42: 145–61CrossRef

58.

Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 1985; 46(8): 20–5PubMed

59.

Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650–6PubMedCrossRef

60.

Bassarath L. Medication strategies in childhood aggression: a review. Can J Psychiatry 2003; 48: 367–73PubMed

61.

Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.J Am Acad Child Adolesc Psychiatry 2003; 42: 132–44PubMedCrossRef

62.

Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27–38PubMed

63.

Kane JM. Extrapyramidal side effects are unacceptable. Eur Neropsychopharmacol 2001; 11Suppl. 4: S397–403CrossRef

64.

Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 2000; 3: 339–49PubMedCrossRef

65.

Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–46PubMed

66.

Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6(3): 177–90PubMedCrossRef

67.

Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33(1): 155–9PubMed

68.

Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997 Jun; 27(3): 313–23PubMedCrossRef

69.

McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997 May; 36(5): 685–93PubMedCrossRef

70.

Buitelaar JK, Van Der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62(4): 239–48PubMedCrossRef

71.

Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41: 1026–36PubMedCrossRef

72.

Findling RL, McNamara NK, Braniky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder.J Am Acad Child Psychiatry 2000; 39(4): 509–16CrossRef

73.

VanBellinghen M, DeTroch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001; 11(1): 5–13PubMedCrossRef

74.

Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005; 44: 64–72PubMedCrossRef

75.

Masi G, Milone A, Canepa G, et al. Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 2006; 21: 51–7PubMedCrossRef

76.

Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacology 2001; 11: 285–8CrossRef

77.

Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000; 26: 62–72PubMed

78.

Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286: 2547–8PubMedCrossRef

79.

Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacotherapy 2000; 39: 509–16

80.

McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004; 65: 20–9PubMed

81.

McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003; 64Suppl. 4: 16–25PubMed

82.

Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997; 58: 12–5PubMedCrossRef

83.

Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157: 818–20PubMedCrossRef

84.

Dale PG. Lithium therapy in aggressive mentally subnormal patients. Br J Psychiatry 1980; 137: 469–74PubMedCrossRef

85.

Delong GR, Aldershof AL. Long-term experience with lithium treatment in childhood: correlation with clinical diagnosis. J Am Acad Child Adolesc Psychiatry 1987; 26: 389–94PubMedCrossRef

86.

Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorder in adolescents. Am J Psychiatry 1997; 154(4): 554–5PubMed

87.

Kafantaris V, Campbell M, Padron-Gayol MV, et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 1992; 28: 193–9PubMed

88.

Gerardin P, Cohen D, Mazet P, et al. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol 2002; 12: 361–70PubMedCrossRef

89.

Soller M, Karnik NS, Steiner H. Psychopharmacologic treatment of juvenile offenders. Child Adolesc Psychiatr Clin N Am 2006; 15: 477–99PubMedCrossRef

90.

Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997; 42: 546–52PubMedCrossRef

91.

Cherek DR, Lane SD, Pietras CJ, et al. Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder. Psychopharmacology (Berl) 2002; 159: 266–74CrossRef

92.

Zubieta JK, Alessi NE. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 1992; 12: 346–51PubMed

93.

Riggs PD, Mikulich SK, Coffman LM, et al. Fluoxetine in drug-dependent delinquents with major depression: an open trial. J Child Adolesc Psychopharmacol 1997; 7(2): 87–95PubMedCrossRef

94.

Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37(12): 1271–8PubMedCrossRef

95.

Bond AL. Antidepressant treatments and human aggression. Eur J Pharmacol 2005; 526: 218–25PubMedCrossRef

96.

US Food and Drug Administration. Antidepressant use in children, adolescents, and adults [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/default.htm [Accessed 2006 May 31]

97.

Eisenberg L, Lachman R, Moiling PA, et al. A psychopharmacologic experiment in a training school for delinquent boys. Am J Orthopsychiatry 1963; 33: 431–47CrossRef

98.

Maletzky B. d-Amphetamine and delinquency: hyperkinesis persisting. Dis Nerv Syst 1974; 35: 543–7PubMed

99.

Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990; 29: 719–23PubMedCrossRef

100.

Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination of both in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000; 39(1): 15–25CrossRef

101.

Scholtens J, Roozen M, Mirmiran M, et al. Role of noradrenaline in behavioral changes after defeat in male and female rats. Behav Brain Res 1990; 36: 199–202PubMedCrossRef

102.

Foote L, Aston-Jones GS. Pharmacology and physiology of central noradrenergic systems. In: Bloom FF, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 335–45

103.

Kemph JP, DeVane CL, Levin GM, et al. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993; 32: 577–81PubMedCrossRef

104.

Henggeler SW, Cunningham PB, Pickrel SG, et al. Multisystemic therapy: an effective violence prevention approach for serious juvenile offenders. J Adolesc 1996; 19: 47–61PubMedCrossRef

105.

Fisher PA, Gunnar MR, Chamberlain P, et al. Preventive intervention for maltreated preschool children: impact on children’s behavior, neuroendocrine activity, and foster parent functioning. J Am Acad Child Adolesc Psychiatry 2000; 39(11): 1356–64PubMedCrossRef

106.

Borduin CM, Henggeler SW, Blaske DM, et al. Multisystemic treatment of adolescent sexual offenders. Int J Offender Ther Comp Criminol 1990; 34: 105–13CrossRef

107.

Chamberlain P, Reid JB. Comparison of two community alternatives to incarceration for chronic juvenile offenders. J Consult Clin Psychol 1998; 66: 624–33PubMedCrossRef

108.

Hill J. Biological, psychological and social processes in the conduct disorders. J Clin Psychol Psychiatry 2002; 43: 133–64CrossRef

109.

Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behavior. Science 1994; 264: 1733–9PubMedCrossRef

110.

Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297: 851–4PubMedCrossRef

111.

Barzman DH, McConville BJ, Masterson B, et al. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype? J Affect Disord 2005; 88: 279–85PubMedCrossRef

112.

Biederman J, Faraone SV, Wozniak J, et al. Parsing the association between bipolar, conduct, and substance use disorders: a familial risk analysis. Biol Psychiatry 2000; 48: 1034–44

113.

Biederman J, Mick E, Wozniak J, et al. Can a subtype of conduct disorder linked to bipolar disorder be identified? Integration of findings from the Massachusetts General Hospital Pediatric Psychopharmacology Research Program. Biol Psychiatry 2003; 53: 952–60PubMedCrossRef

114.

Clingempeel WG, Henggeler SW. Randomized clinical trials, developmental theory, and antisocial youth: guidelines for research. Dev Psychopathol 2002; 14: 695–711PubMedCrossRef

115.

Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157: 17–25PubMedCrossRef

116.

Wiznitzer M, Findling RL. Why do psychiatric drug research in children? Lancet 2003; 361: 1147–8PubMedCrossRef

117.

Carrey N. Developmental neurobiology implications for pediatric psychopharmacology. Can J Psychiatry 2001; 46: 810–8PubMed

118.

Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics 2001; 108: 983–9PubMedCrossRef

Titel: Pharmacological Aspects of the Treatment of Conduct Disorder in Children and Adolescents
verfasst von: Dr Oleg V. Tcheremissine
Lori M. Lieving
Publikationsdatum: 01.07.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 7/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620070-00002

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2006

Retigabine in Partial Seizures

Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?

Economics of Atypical Antipsychotics in Bipolar Disorder

Retigabine